Evidence map›Paper›PMID 33886285›Full record

ArticleJournal of medicinal chemistry2021

Discovery of Nanomolar Melanocortin-3 Receptor (MC3R)-Selective Small Molecule Pyrrolidine Bis-Cyclic Guanidine Agonist Compounds Via a High-Throughput "Unbiased" Screening Campaign.

Skye R Doering, Katie Freeman, Ginamarie Debevec, Phaedra Geer, Radleigh G Santos, Travis M Lavoi, Marc A Giulianotti, Clemencia Pinilla, Jon R Appel, Richard A Houghten and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Skye R DoeringDepartment of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Katie FreemanDepartment of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Ginamarie DebevecFlorida International University, Port St. Lucie, Florida 34987, United States.
Phaedra GeerFlorida International University, Port St. Lucie, Florida 34987, United States.
Radleigh G SantosNova Southeastern University, 3301 College Avenue, Fort Lauderdale, Florida 33314, United States.
Travis M LavoiFlorida International University, Port St. Lucie, Florida 34987, United States.
Marc A GiulianottiFlorida International University, Port St. Lucie, Florida 34987, United States.
Clemencia PinillaFlorida International University, Port St. Lucie, Florida 34987, United States.
Jon R AppelFlorida International University, Port St. Lucie, Florida 34987, United States.
Richard A HoughtenFlorida International University, Port St. Lucie, Florida 34987, United States.
Mark D EricsonDepartment of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-8715-6010
Carrie Haskell-LuevanoDepartment of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-6783-5972

Funding

Melanocortin Receptor Selective LigandsR01DK124504 · NIDDK · UNIVERSITY OF MINNESOTA · PI GIULIANOTTI, MARC, HASKELL-LUEVANO, CARRIE · 2021 to 2024
$2.8M
High throughput in vivo screening: translational generation of novel analgesicsR01DA031370 · NIDA · TORREY PINES INST FOR MOLECULAR STUDIES · PI HOUGHTEN, RICHARD ALLEN · 2011 to 2015
$2.2M
Melanocortin Selective LigandsR01DK091906 · NIDDK · UNIVERSITY OF MINNESOTA · PI HASKELL-LUEVANO, CARRIE · 2012 to 2015
$1.8M
NIDA NIH HHS R01 DA031370NIDDK NIH HHS R01 DK091906NIDDK NIH HHS R01 DK124504
6 · The paper itself

Abstract

The central melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) are key regulators of body weight and energy homeostasis. Herein, the discovery and characterization of first-in-class small molecule melanocortin agonists with selectivity for the melanocortin-3 receptor over the melanocortin-4 receptor are reported. Identified via "unbiased" mixture-based high-throughput screening approaches, pharmacological evaluation of these pyrrolidine bis-cyclic guanidines resulted in nanomolar agonist activity at the melanocortin-3 receptor. The pharmacological profiles at the remaining melanocortin receptor subtypes tested indicated similar agonist potencies at both the melanocortin-1 and melanocortin-5 receptors and antagonist or micromolar agonist activities at the melanocortin-4 receptor. This group of small molecules represents a new area of chemical space for the melanocortin receptors with mixed receptor pharmacology profiles that may serve as novel lead compounds to modulate states of dysregulated energy balance.

Indexed as

AlgorithmsAnimalsDrug Evaluation, PreclinicalEnergy MetabolismGuanidineHigh-Throughput Screening AssaysHumansMiceMice, KnockoutProtein IsoformsPyrrolidinesReceptor, Melanocortin, Type 3Small Molecule LibrariesStructure-Activity RelationshipGuanidineProtein IsoformsPyrrolidinesReceptor, Melanocortin, Type 3Small Molecule Libraries

Identifiers

PMID33886285
PMCPMC8552302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.